Article Text

Download PDFPDF

533 Survival mechanisms common to immunotherapy and drug tolerant persister tumor cells
  1. Maria Davern1,2,
  2. Brenda Chan1,
  3. Lara Bencsics1,
  4. Jasmine Yun-Tong Kung2,
  5. Michael Yorsz1,
  6. Gabriella Stone1,
  7. Michael Olson1,2,
  8. Patrick Lizotte1,
  9. Cloud Paweletz1,
  10. Patrick Bhola1,
  11. Marcela Maus3,
  12. David Barbie1 and
  13. Anthony Letai1,2
  1. 1Dana-Farber Cancer Institute, Boston, MA, USA
  2. 2Harvard Medical School, Boston, MA, USA
  3. 3Massachusetts General Hospital, Boston, MA, USA


Background Persister tumor cells are a discrete and typically undetectable sub-population of cells that survive anti-cancer therapy and are thought to be a major cause of tumor recurrence. Persisters have been identified following both drug- and immunotherapy. The focus of this study is to examine any similarities or differences between immunotherapy persister cells (IPCs) and drug tolerant persister cells (DTPs). Pharmacological agents and immune cells often kill via apoptosis. Therefore, we investigated if reduced apoptotic sensitivity is a shared mechanism common to IPCs and DTPs and whether the use of BH3 mimetics to enhance apoptotic sensitivity could sensitize IPCs and DTPs. We also investigated if IPCs have an altered sensitivity profile to conventional chemotherapy, radiotherapy and epigenetic modulators. Similarly, we assessed the sensitivity of DTPs to T cell attack and radiotherapy.

Methods IPCs were generated by chronically co-culturing tumor cell lines (murine B16-OVA melanoma cells or human HeLa-EGFR cervical tumor cells) with T cells (OVA-T-1 murine T cells or human EGFR-CAR T cells) for 7 days. Six different DTP cell lines were generated by chronically treating tumor cells for 7 days with a high dose of drug that killed approximately 90% of the cells after 3 days (5-FU/oxaliplatin/docetaxel/etoposide/dinaciclib/panobinostat). Using a CellTiter-glo assay, we determined the sensitivity of IPCs and DTPs to drugs, radiation and T cell attack. Microscopy-based BH3 profiling was employed to measure the mitochondrial apoptotic sensitivity of persisters and to determine if there exists any anti-apoptotic dependencies that persisters might rely on to enhance their survival.

Results IPCs acquired a reduced sensitivity to multiple drug classes and radiotherapy. Likewise, DTPs also developed a reduced sensitivity to multiple drug classes and radiotherapy but also acquired a reduced sensitivity to T cell killing. Depending on the cell line and therapy, some persisters developed either an increased or decreased sensitivity to apoptosis. Inhibition of specific anti-apoptotic dependencies using BH3 mimetics increased apoptotic sensitivity of persister cells.

Conclusions We identified that reduced apoptotic sensitivity is a shared mechanism of survival common to many IPCs and DTPs. IPCs and DTPs have distinct anti-apoptotic dependencies compared to their parental cell lines wherein pharmacological inhibition of such dependencies enhanced apoptotic sensitivity. IPCs and DTPs also displayed a reduced sensitivity to other therapies that they were never exposed to suggesting that the acquired mechanisms of resistance to T cell killing or drug therapy also conferred a reduced sensitivity to many drug classes, cellular immunotherapies and radiation.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.